As the US FDA continues its implementation of the 21st Century Cures Act, the agency will be releasing guidance "very soon" on how sponsors can conduct "seamless" trials as part of the law's broader effort to modernize clinical studies, Commissioner Scott Gottlieb announced.
Testifying July 25 before the House Energy and Commerce Subcommittee on Health on the implementation of the Cures Act, Gottlieb explained that the one of the things the guidance will do is explain how drugmakers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?